| scholarly article | Q13442814 |
| P50 | author | Robert Snoeck | Q47921736 |
| Graciela Andrei | Q47921752 | ||
| P2860 | cites work | Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. | Q45780404 |
| Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs | Q46223611 | ||
| Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine | Q46492680 | ||
| Severe eczema vaccinatum in a household contact of a smallpox vaccinee | Q46639360 | ||
| Cowpox infection transmitted from a domestic cat. | Q46804034 | ||
| Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis | Q46860962 | ||
| Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice | Q48312954 | ||
| Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. | Q54117357 | ||
| Smallpox | Q60060914 | ||
| Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase | Q71077818 | ||
| Cidofovir | Q71615638 | ||
| Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates | Q72173262 | ||
| Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma | Q72871557 | ||
| Topical cidofovir for molluscum contagiosum in children | Q73337514 | ||
| Bioavailability and metabolism of cidofovir following topical administration to rabbits | Q73497838 | ||
| Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study | Q74159968 | ||
| Topical cidofovir for severe molluscum contagiosum | Q77904834 | ||
| Dramatic rescue relieves rare case of smallpox infection | Q80265175 | ||
| Transmission of monkeypox among persons exposed to infected prairie dogs in Indiana in 2003 | Q23909258 | ||
| Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate | Q24530586 | ||
| Cellular uptake of phosphonylmethoxyalkylpurine derivatives | Q28325396 | ||
| Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation | Q28379498 | ||
| Efficacy of Multiple- or Single-Dose Cidofovir against Vaccinia and Cowpox Virus Infections in Mice | Q28396760 | ||
| Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection | Q30231576 | ||
| The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. | Q30759685 | ||
| Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. | Q32084536 | ||
| Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. | Q33726237 | ||
| Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro | Q33804593 | ||
| Clinical uses of cidofovir | Q33867391 | ||
| Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. | Q33892331 | ||
| Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses | Q34107597 | ||
| Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro | Q34111476 | ||
| Cidofovir in the treatment of poxvirus infections | Q34134474 | ||
| Efficacy of cidofovir in a murine model of disseminated progressive vaccinia | Q34140816 | ||
| A review of topical and intralesional cidofovir | Q34236016 | ||
| Acyclic nucleoside phosphonates: a key class of antiviral drugs | Q34464655 | ||
| A case of human orf in an immunocompromised patient treated successfully with cidofovir cream | Q34516537 | ||
| Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs | Q34571871 | ||
| Qualitative assessment of risk for monkeypox associated with domestic trade in certain animal species, United States | Q34576518 | ||
| Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections | Q34606754 | ||
| Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. | Q35023111 | ||
| In vitro activity of potential anti-poxvirus agents | Q35077243 | ||
| A review of compounds exhibiting anti-orthopoxvirus activity in animal models | Q35077248 | ||
| Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. | Q35103702 | ||
| Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria | Q35113383 | ||
| Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients | Q35115039 | ||
| Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype | Q35215440 | ||
| Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. | Q35547866 | ||
| Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections | Q35558801 | ||
| Human monkeypox: an emerging zoonosis | Q35628219 | ||
| Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge | Q35685188 | ||
| Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment | Q36631850 | ||
| Isolation and characterization of cidofovir resistant vaccinia viruses | Q36678276 | ||
| Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox | Q37033408 | ||
| Cowpox virus infection: an emerging health threat | Q37100940 | ||
| The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination | Q37157260 | ||
| Cowpox virus transmission from pet rats to humans, France | Q37203679 | ||
| Cowpox virus transmission from pet rats to humans, Germany | Q37203719 | ||
| Progress in the discovery of compounds inhibiting orthopoxviruses in animal models | Q37331541 | ||
| Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. | Q37401749 | ||
| Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir | Q37488882 | ||
| Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro | Q37734396 | ||
| Biochemical pharmacology of acyclic nucleotide analogues | Q37783046 | ||
| Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model | Q38460330 | ||
| Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. | Q38477864 | ||
| Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. | Q38482641 | ||
| Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice | Q38760673 | ||
| Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus | Q39804417 | ||
| Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir | Q39869286 | ||
| Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity | Q40065243 | ||
| Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). | Q40156820 | ||
| Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds | Q40171474 | ||
| Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro | Q40325993 | ||
| Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures | Q40348369 | ||
| Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines | Q40358241 | ||
| Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds | Q40552798 | ||
| 5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity | Q40621753 | ||
| Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections | Q40666918 | ||
| A novel selective broad-spectrum anti-DNA virus agent | Q40804246 | ||
| Parapoxviruses are strongly inhibited in vitro by cidofovir | Q40829323 | ||
| Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells | Q41148686 | ||
| Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines | Q41270617 | ||
| Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus | Q41343033 | ||
| Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs | Q41361126 | ||
| Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand | Q41915115 | ||
| Human cowpox in a veterinary student | Q43119827 | ||
| Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. | Q43261185 | ||
| Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir | Q43485506 | ||
| Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection | Q43690814 | ||
| Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice | Q43719348 | ||
| Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs | Q43741891 | ||
| Topical use of cidofovir induced acute renal failure | Q43914181 | ||
| Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug | Q44025971 | ||
| Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells | Q44164228 | ||
| Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. | Q44329265 | ||
| Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice | Q44483465 | ||
| Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures | Q44594293 | ||
| (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue | Q44677601 | ||
| Intralesional cidofovir and surgical excision for laryngeal papillomatosis | Q44683735 | ||
| Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease | Q44718436 | ||
| Topical cidofovir and cryotherapy--combination treatment for recalcitrant molluscum contagiosum in a patient with HIV infection | Q44792068 | ||
| A 17-year-old girl with a black eschar. Cowpox virus infection | Q44840225 | ||
| Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir | Q44936207 | ||
| Cidofovir plasma assays after local injection in respiratory papillomatosis | Q44964837 | ||
| Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. | Q44970891 | ||
| Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro | Q45212219 | ||
| Cidofovir diphosphate inhibits molluscum contagiosum virus DNA polymerase activity | Q45399247 | ||
| In vivo imaging of cidofovir treatment of cowpox virus infection. | Q45403628 | ||
| Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod | Q45404387 | ||
| Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection | Q45415555 | ||
| The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4. | Q45493777 | ||
| Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir | Q45740776 | ||
| Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. | Q45741202 | ||
| Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge | Q45745500 | ||
| Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir | Q45761008 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P304 | page(s) | 2803-2830 | |
| P577 | publication date | 2010-12-22 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Cidofovir Activity against Poxvirus Infections | |
| P478 | volume | 2 |
| Q44205846 | Autoinoculation with Orf virus (ecthyma contagiosum). |
| Q47547852 | Challenges and Achievements in Prevention and Treatment of Smallpox |
| Q47558565 | Disaster Preparedness: Biological Threats and Treatment Options |
| Q34606386 | Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals |
| Q37544535 | KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo |
| Q37173398 | Orthopoxvirus targets for the development of new antiviral agents. |
| Q28294254 | Poxvirus DNA replication |
| Q37539293 | Serro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans |
| Q47107948 | Suppression of Poxvirus Replication by Resveratrol |
| Q39118775 | The vaccinia virus DNA polymerase and its processivity factor |
| Q38797660 | Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. |
Search more.